CGTX Cognition Therapeutics Inc.

12
-0.16  -1%
Previous Close 12.16
Open 12.28
52 Week Low 11.9
52 Week High 13.8
Market Cap $256,456,944
Shares 21,371,412
Float 12,172,329
Enterprise Value $268,821,654
Volume 37,087
Av. Daily Volume 82,783
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
CT1812 - SHINE
Mild-to-Moderate Alzheimer's Disease
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
CT1812
Dementia with Lewy Bodies
Phase 1
Phase 1
Phase 1 ongoing. Phase 2 expected to initiate 2H 2021
CT1812 - SEQUEL
Mild-to-Moderate Alzheimer's Disease
Phase 2
Phase 2
Phase 2 study ongoing
CT1812
Dry Age-related Macular Degeneration (AMD)
Phase 1
Phase 1
Phase 1 ongoing. Phase 2 expected to initiate 2H 2021
CT1812 - COG0203
Early-stage Alzheimer's Disease
Phase 1
Phase 1
Phase 2 to initiate 1H 2022

Latest News

  1. PITTSBURGH, Oct. 12, 2021 /PRNewswire/ -- Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cognition Therapeutics, Inc., launched an initial public offering on Friday, October 8, 2021, trading on the Nasdaq Global Market under the ticker symbol "CGTX." Cognition Therapeutics' IPO is expected to generate approximately $45.2 million in gross proceeds.

    Cognition Therapeutics has discovered and is developing a pipeline of novel, disease modifying, oral drug candidates to treat a broad array of neurodegenerative and neuro-ophthalmic disorders. The company's pipeline compounds uniquely target the sigma-2 (σ-2) receptor, a key regulator of the cellular damage response. CT1812, the lead product candidate…

    PITTSBURGH, Oct. 12, 2021 /PRNewswire/ -- Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cognition Therapeutics, Inc., launched an initial public offering on Friday, October 8, 2021, trading on the Nasdaq Global Market under the ticker symbol "CGTX." Cognition Therapeutics' IPO is expected to generate approximately $45.2 million in gross proceeds.

    Cognition Therapeutics has discovered and is developing a pipeline of novel, disease modifying, oral drug candidates to treat a broad array of neurodegenerative and neuro-ophthalmic disorders. The company's pipeline compounds uniquely target the sigma-2 (σ-2) receptor, a key regulator of the cellular damage response. CT1812, the lead product candidate, is being assessed in a comprehensive clinical program for Alzheimer's disease.

    PLSG was Cognition Therapeutics' first investor and was instrumental in generating follow-on investments from the region. In addition, PLSG brought the company to Pittsburgh by providing the company with its first chief executive officer and laboratory located in Pittsburgh's South Side.

    "PLSG identified early on the strength of the technology and worked diligently to provide the support needed for success," said PLSG CEO Diana Cugliari. "We are so excited that this technology has now generated the funding to bring potentially life changing therapy to so many patients and their families who are suffering from neurodegenerative and neuro-ophthalmic disorders, including Alzheimer's."

    The influx of capital PLSG expects to receive from Cognition Therapeutics' IPO will be reinvested back into the region to support the efforts of other life sciences startup companies, simultaneously cultivating scientific breakthroughs, strengthening our region's economy, and creating jobs.

    "The success of Cognition Therapeutics underscores the mission of PLSG – perpetuating the cycle of life sciences startup companies from inception to commercialization and leveraging that success to grow the next generation of life sciences companies to enrich our region's economy as well as advance scientific discovery. This is a great economic development success story for the region and for the Commonwealth of Pennsylvania, who have steadfastly supported our efforts," said Ms. Cugliari.

    The Pittsburgh Life Sciences Greenhouse (PLSG) is a comprehensive life sciences economic development organization. We are dedicated to advancing life sciences in western Pennsylvania by building on the region's strengths in research, clinical care and life sciences entrepreneurship. We serve our community by providing knowledge, connection and capital to help companies grow, create jobs and improve the health of all humanity. For more information, please visit www.plsg.com.

    Cision View original content:https://www.prnewswire.com/news-releases/pittsburgh-life-sciences-greenhouse-proudly-announces-ipo-of-portfolio-company-cognition-therapeutics-301398272.html

    SOURCE Pittsburgh Life Sciences Greenhouse

    View Full Article Hide Full Article
  2. PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of $12.00 per share. All of the shares of common stock are being offered by Cognition. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cognition, are expected to be approximately $45.2 million…

    PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of $12.00 per share. All of the shares of common stock are being offered by Cognition. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cognition, are expected to be approximately $45.2 million.

    Cognition's common stock is expected to begin trading on the Nasdaq Global Market on October 8, 2021 under the ticker symbol "CGTX." The offering is expected to close on October 13, 2021, subject to the satisfaction of customary closing conditions. In addition, Cognition has granted the underwriters a 45-day option to purchase up to an additional 565,217 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

    B. Riley Securities, Inc. is acting as the lead bookrunning manager and Oppenheimer & Co. is acting as joint bookrunning manager. Troutman Pepper Hamilton Sanders LLP is representing the Company and McGuireWoods LLP is representing the underwriters.

    Registration statements relating to the shares being sold in this offering were filed with the Securities and Exchange Commission and became effective on October 7, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from B. Riley Securities, Inc., Attention: Prospectus Department, 1300 North 17th Street, Suite 1300, Arlington, Virginia 22209, or by telephone at 703-312-9580, or by email at prospectuses@brileyfin.com; or from Oppenheimer & Co., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, or by telephone at 212-667-8055, or by email at EquityProspectus@opco.com.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Cognition Therapeutics

    Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.

    Forward-Looking Statements

    This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing, and size of the proposed initial public offering of our common stock and the expected commencement of trading on the Nasdaq Global Market. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to market conditions and satisfaction of customary closing conditions related to the proposed initial public offering. There can be no assurance that we will be able to complete our initial public offering on the anticipated terms, or at all. Applicable risks also include those identified under the heading "Risk Factors" in Cognition's registration statement on Form S-1. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

    Contact Information:

    Cognition Therapeutics, Inc.

    info@cogrx.com

    Aline Sherwood (media)

    Scienta Communications

    asherwood@scientapr.com

    Lisa Sher (investors)

    Tiberend Strategic Advisors, Inc.

    lsher@tiberend.com

     



    Primary Logo

    View Full Article Hide Full Article
View All Cognition Therapeutics Inc. News